Drug Trial Radar · NCT01141439
Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
Last checked: Nov 19, 2026Latest source record: Mar 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
815,377
Actual
Start
Jan 2001
Primary completion
Jun 2007
Study completion Jul 2010
Sponsor
- Lead sponsor
- Research in Real-Life LtdResearch network
- Sponsor type
- Research network
- Collaborators
- Teva Branded Pharmaceutical Products R&D, Inc.
- First posted
- Jun 10, 2010
Design
- Study type
- Observational
- Who can join
- All sexes, from 5 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation and increased dose of inhaled corticosteroid (ICS) therapy using HFA-BDP (Qvar®) (either as initial therapy or as a step-up therapy) compared with the most commonly prescribed alternative ICS in the UK, CFC-beclometasone (BDP) and fluticasone (FP) as metered dose inhalers (MDIs). Qvar vs FP analyses were split between adults (12-60yrs) and paediatrics (5-11yrs).
Conditions
- Asthma
Interventions
Extra-fine hydrofluoroalkane-beclomethasone dipropionateDrug
Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
Extra-fine hydrofluoroalkane-beclomethasone dipropionateDrug
An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
Fluticasone propionateDrug
An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
Beclomethasone dipropionateDrug
An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
fluticasone propionateDrug
Initiation of FP (any dose) via MDI in steroid naive patient
Chlorofluorocarbon beclomethasone dipropionateDrug
Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proxy asthma controlTime frame: One-year outcome period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Practice Research Database
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.